Article | June 22, 2022

FDA Guidance For Diversity In Clinical Trials: What You Need To Know

By Taylor Davidson, Florence Healthcare

Diversity GettyImages-1299265628

The FDA’s newest guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials,” took the clinical research world by storm. 

While diversity, equity, and inclusion have been major focuses for clinical research teams for a long time, sponsors and sites were excited and surprised to receive explicit FDA guidance in April 2022. 

But what do clinical research teams need to know from the guidance, and how can we prepare to incorporate it?

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader